Skip to content

King Pharmaceuticals KG Program Services — Net loss and loss adjustment expenses

Other segment segments

Legacy Reinsurance
$2.26M

Similar metrics at other companies

Markel logo
MKLProgram Services — Unpaid losses and loss adjustment expenses
$1.3B
Markel logo
MKLProgram Services — Liability for Unpaid Claims and Claims Adjustment Expense, Net
$0
SiriusPoint logo
SPNTInsurance & Services — Loss and loss adjustment expenses incurred, net
$215.7M+2.8%
PRA
PRASpecialty P&C — Net losses and loss adjustment expenses
$137.59M-9.6%
Arch Capital Group logo
ACGLInsurance — Net Losses and Loss Adjustment Expenses Incurred
$1.19B+17.1%
SiriusPoint logo
SPNTReinsurance — Loss and loss adjustment expenses incurred, net
$134M-31.4%

Other financials

Income statement

See full
Revenue$10.2M+1,112%
Net income-$7.4M-1,786%
EPS (diluted)-$0.96-586%

Balance sheet

See full
Cash & equivalents$62.2M+1,724%
Total debt$176.7M
Total equity$121.4M+2,773%
Total assets$964.2M

Cash flow

See full
Operating cash flow-$15.1M-1,628%

Valuation

See full
Market cap$70.42M-67.6%
Enterprise value$184.93M-50.0%
P/E1.2×
P/S1.6×-24.3×

Profitability

See full
Net margin131.5%

Returns & leverage

See full
Return on equity90.8%
Debt / equity1.5×

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PolicyholderBenefitsAndClaimsIncurredNet.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's program services — net loss and loss adjustment expenses.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is King Pharmaceuticals's program services — net loss and loss adjustment expenses?
King Pharmaceuticals (KG) reported program services — net loss and loss adjustment expenses of $0 in Q1 2026.
What does program services — net loss and loss adjustment expenses mean?
The total costs incurred for claims and the associated expenses to investigate and settle those claims, net of reinsurance recoveries. This is a critical measure of the segment's underwriting quality and claims management efficiency.